Sight Sciences, Inc. (SGHT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SGHT SEC filings page.
Sight Sciences, Inc. (SGHT) reported $83.4M in revenue over the twelve months to Jun 30, 2026, up 9.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sight Sciences is becoming less loss-making through cost reductions, while persistent cash use steadily weakens its equity cushion.
Revenue was lower in FY2025 than FY2023, yet operating margin improved from-70.7% to-48.0% . That change coincided with SG&A falling from$108.9M to$89.2M , so the improvement looks driven primarily by cost reduction rather than scale-driven growth.
Gross margin expanded from
FY2025 net loss was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sight Sciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sight Sciences, Inc. held $92.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $29.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Sight Sciences, Inc. scores 61/100 among other emerging companies.
Sight Sciences, Inc. had 54M shares outstanding at the end of fiscal year 2025, against 51M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Sight Sciences, Inc. scores 59/100 among other emerging companies.
Sight Sciences, Inc. spent $14.6M on research and development in fiscal year 2025, which was 12.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Sight Sciences, Inc. scores 41/100 among other emerging companies.
Sight Sciences, Inc. reported revenue of $77.4M in fiscal year 2025, against $79.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Sight Sciences, Inc. scores 41/100 among other emerging companies.
Sight Sciences, Inc.'s operations used $29.7M of cash in fiscal year 2025, against $22.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Sight Sciences, Inc. scores 65/100 among other emerging companies.
Sight Sciences, Inc.'s cash, cash equivalents and investments came to $92.0M at the end of fiscal year 2025, against $51.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Sight Sciences, Inc. scores 72/100 among other emerging companies.
Sight Sciences, Inc. scores 1.45, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($466.6M) relative to total liabilities ($51.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sight Sciences, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Sight Sciences, Inc. reported a net loss of $38.4M while operations used $29.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Sight Sciences, Inc. reported an operating loss of $37.1M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Sight Sciences, Inc. generated $23.4M in revenue in Q2 2026. This represents an increase of 19.5% from the same quarter a year earlier. Against the prior quarter it is up 18.7%.
Sight Sciences, Inc.'s EBITDA was -$3.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 67.3% from the same quarter a year earlier. Against the prior quarter it is up 69.2%.
Sight Sciences, Inc. reported -$4.4M in net income in Q2 2026. This represents an increase of 62.8% from the same quarter a year earlier. Against the prior quarter it is up 65.7%.
Sight Sciences, Inc. earned -$0.08 per diluted share (EPS) in Q2 2026. This represents an increase of 65.2% from the same quarter a year earlier. Against the prior quarter it is up 66.7%.
Cash & Balance Sheet
Sight Sciences, Inc. recorded an outflow of $5.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 26.7% from the same quarter a year earlier. Against the prior quarter it is up 19.8%.
Sight Sciences, Inc. held $79.8M in cash against $30.6M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Sight Sciences, Inc.'s gross margin was 91.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 6.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.2 percentage points.
Sight Sciences, Inc.'s operating margin was -16.6% in Q2 2026, reflecting core business profitability. This is up 43.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 46.4 percentage points.
Sight Sciences, Inc.'s net profit margin was -19.0% in Q2 2026, showing the share of revenue converted to profit. This is up 42.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 46.9 percentage points.
Sight Sciences, Inc.'s ROE was -8.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.7 percentage points.
Capital Allocation
Sight Sciences, Inc. invested $2.5M in research and development in Q2 2026. This represents a decrease of 42.7% from the same quarter a year earlier. Against the prior quarter it is down 1.3%.
Sight Sciences, Inc. invested $19K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 91.0% from the same quarter a year earlier. Against the prior quarter it is down 68.3%.
Not reported for Q2 2026.
SGHT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.4M+19.5% | $19.7M+12.5% | $20.4M+6.9% | $19.9M-1.2% | $19.6M-8.5% | $17.5M-9.1% | $19.1M+1.7% | $20.2M+0.7% |
| Cost of Revenue | $2.0M-32.3% | $2.7M+12.7% | $2.6M+3.3% | $2.7M-16.6% | $3.0M-1.6% | $2.4M-13.6% | $2.5M-9.4% | $3.3M+21.4% |
| Gross Profit | $21.4M+28.9% | $17.0M+12.5% | $17.8M+7.4% | $17.2M+1.7% | $16.6M-9.6% | $15.1M-8.4% | $16.6M+3.7% | $16.9M-2.5% |
| R&D Expenses | $2.5M-42.7% | $2.5M-42.5% | $2.4M-43.2% | $3.4M-29.4% | $4.4M+1.6% | $4.4M-4.4% | $4.3M+25.3% | $4.7M+12.0% |
| SG&A Expenses | $22.8M-4.7% | $26.8M+9.5% | $19.0M-21.4% | $21.8M-7.0% | $23.9M-10.5% | $24.5M-7.7% | $24.2M+2.3% | $23.4M-11.7% |
| Operating Income | -$3.9M+66.7% | -$12.4M+10.4% | -$3.7M+69.3% | -$7.9M+29.6% | -$11.7M+7.8% | -$13.9M+5.9% | -$11.9M-7.4% | -$11.2M+16.3% |
| EBITDA | -$3.8M+67.3% | -$12.3M+10.2% | -$3.5M+69.6% | -$7.8M+29.9% | -$11.6M+7.8% | -$13.7M+5.6% | -$11.6M-6.1% | -$11.1M+15.8% |
| Interest Expense | $1.3M+0.5% | $1.3M+0.4% | $1.3M+10.9% | $1.3M+13.5% | $1.3M+12.1% | $1.3M+4.9% | $1.2M-14.0% | $1.2M-19.6% |
| Income Tax | $28K-30.0% | $11K-73.2% | $8K-78.9% | -$79K-147.6% | $40K+166.7% | $41K+141.2% | $38K+280.0% | $166K+112.8% |
| Net Income | -$4.4M+62.8% | -$13.0M+8.3% | -$4.2M+64.9% | -$8.2M+26.2% | -$11.9M+3.1% | -$14.2M+13.0% | -$11.8M-10.8% | -$11.1M+15.1% |
| EPS (Basic) | -$0.08+65.2% | -$0.24+14.3% | -$0.08+66.7% | -$0.16+27.3% | -$0.23+8.0% | -$0.28+15.2% | -$0.24-9.1% | -$0.22+18.5% |
| EPS (Diluted) | -$0.08+65.2% | -$0.24+14.3% | -$0.08+66.7% | -$0.16+27.3% | -$0.23+8.0% | -$0.28+15.2% | -$0.24-9.1% | -$0.22+18.5% |
| Diluted Shares (Avg) | 55M+5.2% | 54M+5.2% | N/A | 52M+4.0% | 52M+3.8% | 51M+3.6% | N/A | 50M+3.4% |
SGHT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $104.9M-14.0% | $109.7M-15.4% | $115.3M-19.3% | $116.3M-19.0% | $122.0M-18.5% | $129.7M-16.6% | $142.8M-14.3% | $143.6M-18.7% |
| Current Assets | $101.4M-15.1% | $106.5M-16.1% | $112.7M-19.3% | $113.6M-19.1% | $119.4M-18.4% | $126.9M-16.6% | $139.8M-14.2% | $140.5M-19.1% |
| Cash & Equivalents | $79.8M-21.4% | $85.0M-21.9% | $92.0M-23.6% | $92.4M-22.1% | $101.5M-14.1% | $108.8M-14.5% | $120.4M-12.9% | $118.6M-17.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $5.7M-8.4% | $7.0M+20.7% | $7.8M+22.8% | $8.0M+31.1% | $6.2M-8.4% | $5.8M-15.5% | $6.3M-19.4% | $6.1M-34.1% |
| Accounts Receivable | $11.4M+18.4% | $10.6M+12.4% | $9.7M-9.7% | $9.7M-24.6% | $9.6M-51.7% | $9.4M-39.8% | $10.8M-24.5% | $12.9M-23.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $52.0M0.0% | $55.8M+7.2% | $51.4M-7.2% | $52.0M+6.8% | $52.0M+8.1% | $52.1M+12.3% | $55.3M+19.1% | $48.6M-1.9% |
| Current Liabilities | $20.5M+71.7% | $18.2M+49.8% | $11.0M-28.7% | $11.8M-14.3% | $11.9M-10.2% | $12.1M+3.7% | $15.5M+26.2% | $13.8M-3.7% |
| Non-Current Liabilities | $31.5M-21.3% | $37.6M-5.7% | $40.3M+1.2% | $40.1M+15.2% | $40.0M+15.0% | $39.9M+15.2% | $39.8M+16.6% | $34.8M-1.1% |
| Long-Term Debt | $30.6M-23.0% | $36.7M-7.2% | $40.3M+2.4% | $40.1M+17.3% | $39.8M+17.9% | $39.6M+17.5% | $39.4M+24.1% | $34.2M+1.1% |
| Total Equity | $52.9M-24.5% | $53.9M-30.6% | $63.9M-26.9% | $64.3M-32.3% | $70.0M-31.1% | $77.6M-28.9% | $87.5M-27.2% | $95.0M-25.3% |
| Retained Earnings | -$402.1M-8.0% | -$397.7M-10.3% | -$384.7M-11.1% | -$380.6M-13.8% | -$372.4M-15.2% | -$360.5M-15.9% | -$346.3M-17.5% | -$334.5M-17.7% |
Not reported in any period shown, so not listed: Goodwill.
SGHT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.7M+24.9% | -$7.0M+39.4% | -$1.8M+47.2% | -$8.7M-2508.6% | -$7.5M+20.3% | -$11.6M-18.6% | -$3.5M+46.7% | $362K+103.7% |
| Depreciation & Amortization | $100K0.0% | $103K-30.9% | $108K-38.6% | $100K0.0% | $100K0.0% | $149K-22.4% | $176K+10.7% | $100K-50.0% |
| Stock-Based Compensation | $3.0M-22.9% | $2.9M-32.8% | N/A | $2.4M-43.8% | $3.8M-11.0% | $4.2M-5.8% | N/A | $4.3M+11.7% |
| Capital Expenditures | $19K-91.0% | $60K | -$156K+13.9% | $170K+233.3% | $210K+162.5% | $0-100.0% | $137K-48.1% | $51K-83.2% |
| Free Cash Flow | -$5.7M+26.7% | -$7.1M+38.9% | -$2.0M+44.9% | -$8.9M-2958.2% | -$7.8M+18.8% | -$11.6M-17.2% | -$3.6M+46.7% | $311K+103.1% |
| Investing Cash Flow | -$19K+91.0% | -$60K | $156K+213.9% | -$170K-233.3% | -$210K-162.5% | $0+100.0% | -$137K+48.1% | -$51K+83.2% |
| Financing Cash Flow | $474K-2.3% | $88K+450.0% | $1.3M-76.5% | $25K-67.1% | $485K+10.0% | $16K+101.7% | $5.4M+1333.2% | $76K-35.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SGHT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.4%+6.6pp | 86.2%0.0pp | 87.3%+0.4pp | 86.4%+2.5pp | 84.8%-1.1pp | 86.2%+0.7pp | 86.8%+1.6pp | 83.9%-2.7pp |
| Operating Margin | -16.6%+43.0pp | -63.0%+16.1pp | -18.0%+44.5pp | -39.7%+16.0pp | -59.6%-0.4pp | -79.2%-2.7pp | -62.5%-3.3pp | -55.7%+11.3pp |
| Net Margin | -19.0%+42.0pp | -65.9%+14.9pp | -20.4%+41.7pp | -41.0%+13.9pp | -61.0%-3.4pp | -80.8%+3.6pp | -62.1%-5.1pp | -54.9%+10.2pp |
| Return on Equity | -8.4%+8.7pp | -24.1%-5.8pp | -6.5%+7.0pp | -12.7%-1.1pp | -17.1%-4.9pp | -18.2%-3.3pp | -13.5%-4.6pp | -11.7%-1.4pp |
| Return on Assets | -4.2%+5.5pp | -11.8%-0.9pp | -3.6%+4.7pp | -7.0%+0.7pp | -9.8%-1.6pp | -10.9%-0.5pp | -8.3%-1.9pp | -7.7%-0.3pp |
| Current Ratio | 4.95-5.1x | 5.86-4.6x | 10.22+1.2x | 9.60-0.6x | 10.01-1.0x | 10.47-2.5x | 9.04-4.3x | 10.18-1.9x |
| Debt-to-Equity | 0.580.0x | 0.68+0.2x | 0.63+0.2x | 0.62+0.3x | 0.57+0.2x | 0.51+0.2x | 0.45+0.2x | 0.36+0.1x |
| Asset Turnover | 0.22+0.1x | 0.180.0x | 0.180.0x | 0.170.0x | 0.160.0x | 0.140.0x | 0.130.0x | 0.140.0x |
| FCF Margin | -24.3%+15.3pp | -36.0%+30.3pp | -9.7%+9.1pp | -44.6%-46.2pp | -39.6%+5.0pp | -66.3%-14.9pp | -18.9%+17.1pp | 1.5%+52.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Sight Sciences, Inc. SGHT | FY2025 | $77.4M | -$38.4M | -49.7% | $466.6M | 57/100 |
| CVRx, Inc. CVRX | FY2025 | $56.7M | -$53.3M | -94.1% | $43.2M | 50/100 |
| BioSig Technologies, Inc. BSGM | FY2025 | N/A | -$462.8M | N/A | $157.0M | — |
| Electromed, Inc. ELMD | FY2026 | $73.8M | $11.3M | 15.3% | $234.3M | 79/100 |
| Accuray Incorporated ARAY | FY2026 | $401.9M | -$49.2M | -12.2% | $31.2M | 22/100 |
| Monogram Technologies Inc. MGRM | FY2024 | N/A | -$16.3M | N/A | $243.8M | — |
Where Sight Sciences, Inc. Ranks
Frequently Asked Questions
What is Sight Sciences, Inc.'s annual revenue?
Sight Sciences, Inc. (SGHT) reported $77.4M in total revenue for fiscal year 2025. This represents a -3.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sight Sciences, Inc.'s revenue growing?
Sight Sciences, Inc. (SGHT) revenue declined by 3.1% year-over-year, from $79.9M to $77.4M in fiscal year 2025.
Is Sight Sciences, Inc. profitable?
No, Sight Sciences, Inc. (SGHT) reported a net income of -$38.4M in fiscal year 2025, with a net profit margin of -49.7%.
What is Sight Sciences, Inc.'s EBITDA?
Sight Sciences, Inc. (SGHT) had EBITDA of -$36.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Sight Sciences, Inc. have?
As of fiscal year 2025, Sight Sciences, Inc. (SGHT) had $92.0M in cash and equivalents against $40.3M in long-term debt.
What is Sight Sciences, Inc.'s gross margin?
Sight Sciences, Inc. (SGHT) had a gross margin of 86.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sight Sciences, Inc.'s operating margin?
Sight Sciences, Inc. (SGHT) had an operating margin of -47.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sight Sciences, Inc.'s net profit margin?
Sight Sciences, Inc. (SGHT) had a net profit margin of -49.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sight Sciences, Inc.'s return on equity (ROE)?
Sight Sciences, Inc. (SGHT) has a return on equity of -60.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sight Sciences, Inc.'s free cash flow?
Sight Sciences, Inc. (SGHT) recorded an outflow of $29.9M in free cash flow during fiscal year 2025. This represents a -31.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sight Sciences, Inc.'s operating cash flow?
Sight Sciences, Inc. (SGHT) recorded an outflow of $29.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sight Sciences, Inc.'s total assets?
Sight Sciences, Inc. (SGHT) had $115.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sight Sciences, Inc.'s capital expenditures?
Sight Sciences, Inc. (SGHT) invested $224K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sight Sciences, Inc. spend on research and development?
Sight Sciences, Inc. (SGHT) invested $14.6M in research and development during fiscal year 2025.
What is Sight Sciences, Inc.'s current ratio?
Sight Sciences, Inc. (SGHT) had a current ratio of 10.22 as of fiscal year 2025, which is generally considered healthy.
What is Sight Sciences, Inc.'s debt-to-equity ratio?
Sight Sciences, Inc. (SGHT) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sight Sciences, Inc.'s return on assets (ROA)?
Sight Sciences, Inc. (SGHT) had a return on assets of -33.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sight Sciences, Inc.'s P/E ratio?
Sight Sciences, Inc. (SGHT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $466.6M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Sight Sciences, Inc.'s price-to-sales ratio?
Sight Sciences, Inc. (SGHT) trades at 5.6x sales, its market capitalization divided by revenue of $83.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $466.6M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Sight Sciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Sight Sciences, Inc. (SGHT) held $92.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.7M over that year. Dividing the one by the other, the reported balance equals about 37 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Sight Sciences, Inc.'s Altman Z-Score?
Sight Sciences, Inc. (SGHT) has an Altman Z-Score of 1.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sight Sciences, Inc.'s Piotroski F-Score?
Sight Sciences, Inc. (SGHT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sight Sciences, Inc.'s earnings high quality?
Sight Sciences, Inc. (SGHT) reported a net loss of $38.4M while operations used $29.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sight Sciences, Inc. cover its interest payments?
Sight Sciences, Inc. (SGHT) reported an operating loss of $37.1M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sight Sciences, Inc.?
Sight Sciences, Inc. (SGHT) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.